64Cu-DOTATATE PET/CT Predicts Progression-Free Survival in Patients with Neuroendocrine Neoplasms Abstract #2717

Introduction: The degree of overexpression of somatostatin receptors in patients with neuroendocrine neoplasms (NEN) may reflect tumor differentiation and thus be associated with prognosis. Non-invasive quantification of receptor density is possible by somatostatin receptor imaging (SRI) using positron emission tomography (PET).
Aim(s): Recently, we introduced 64Cu-DOTATATE PET/CT for SRI and we hypothesized that tracer uptake could be associated with overall survival (OS) and progression-free survival (PFS).
Materials and methods: We evaluated patients with NEN that had a 64Cu-DOTATATE PET/CT performed in previous prospective studies. Tracer uptake was determined as the maximal standardized uptake value (SUVmax) for each patient. Optimal cutoff for SUVmax and the hazard ratio for PFS and OS were determined. Specificity, sensitivity and accuracy were calculated for prediction of outcome at 24 months after 64Cu-DOTATATE PET/CT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Esben Andreas Carlsen

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1789 FDG-PET is Superior to WHO Grading in Predicting Overall Survival of Patients with Neuroendocrine Tumors: A Prospective Study of 172 Patients
Introduction: Accurate grading of patients with neuroendocrine tumors (NETs) is essential for risk stratification and optimal choice of therapy. Currently, WHO grading is based on histo-pathologically assessed degree of tumor proliferation.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Andreas Kjær
Keywords: PET, PET/CT, imaging, survival
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2715 The Role of Serum Concentration Ratio of Neuron-Specific Enolase in the Evaluation of Therapeutic Effect of Neuroendocrine Tumor
Introduction: There has been no good serum biomarker for the evaluation of the therapeutic effect of Neuroendocrine tumors(NET)
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Kan Jingbao
Authors: Jingbao K, ...
#2724 Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Anna Łowczak
#2725 Upfront Surgery in Patients with High-Grade GEP NEN and MINEN: A Nordic Multicenter Study of 201 Patients
Introduction: Surgery is the principal treatment for loco-regional gastroenteropancreatic (GEP) neuroendocrine tumors (NET). However, whether surgery is beneficial in high-grade neuroendocrine neoplasms (NEN) and mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN) is not known.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD, PhD Hans-Christian Pommergaard